Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework.

[1]  Johan Desmet,et al.  The dead-end elimination theorem and its use in protein side-chain positioning , 1992, Nature.

[2]  P. Koehl,et al.  Application of a self-consistent mean field theory to predict protein side-chains conformation and estimate their conformational entropy. , 1994, Journal of molecular biology.

[3]  Larry Reznick,et al.  Setting priorities , 1994 .

[4]  P. Kollman,et al.  A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .

[5]  Deborah Fass,et al.  Core Structure of gp41 from the HIV Envelope Glycoprotein , 1997, Cell.

[6]  K. Wüthrich,et al.  Torsion angle dynamics for NMR structure calculation with the new program DYANA. , 1997, Journal of molecular biology.

[7]  S L Mayo,et al.  Coupling backbone flexibility and amino acid sequence selection in protein design , 1997, Protein science : a publication of the Protein Society.

[8]  P S Kim,et al.  Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[9]  P. S. Kim,et al.  HIV Entry and Its Inhibition , 1998, Cell.

[10]  John L. Klepeis,et al.  Free energy calculations for peptides via deterministic global optimization , 1999 .

[11]  P. S. Kim,et al.  Inhibiting HIV-1 Entry Discovery of D-Peptide Inhibitors that Target the gp41 Coiled-Coil Pocket , 1999, Cell.

[12]  M. Levitt,et al.  De novo protein design. II. Plasticity in sequence space. , 1999, Journal of molecular biology.

[13]  J. L. Klepeis,et al.  Predicting peptide structures using NMR data and deterministic global optimization , 1999 .

[14]  M. Levitt,et al.  De novo protein design. I. In search of stability and specificity. , 1999, Journal of molecular biology.

[15]  D. Baker,et al.  Native protein sequences are close to optimal for their structures. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[16]  S. L. Mayo,et al.  Conformational splitting: A more powerful criterion for dead‐end elimination , 2000, J. Comput. Chem..

[17]  M. Dierich,et al.  N- and C-domains of HIV-1 gp41: mutation, structure and functions. , 2001, Immunology letters.

[18]  D. Baker,et al.  2.1 and 1.8 A average C(alpha) RMSD structure predictions on two small proteins, HP-36 and s15. , 2001, Journal of the American Chemical Society.

[19]  D. Baker,et al.  De novo determination of protein backbone structure from residual dipolar couplings using Rosetta. , 2002, Journal of the American Chemical Society.

[20]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[21]  Jeffery G Saven,et al.  Combinatorial protein design. , 2002, Current opinion in structural biology.

[22]  Samuel K Sia,et al.  Short constrained peptides that inhibit HIV-1 entry , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[23]  David Baker,et al.  Protein–protein docking predictions for the CAPRI experiment , 2003, Proteins.

[24]  D. Baker,et al.  A large scale test of computational protein design: folding and stability of nine completely redesigned globular proteins. , 2003, Journal of molecular biology.

[25]  Jinming Zou,et al.  Using self-consistent fields to bias Monte Carlo methods with applications to designing and sampling protein sequences , 2003 .

[26]  C. Floudas,et al.  ASTRO-FOLD: a combinatorial and global optimization framework for Ab initio prediction of three-dimensional structures of proteins from the amino acid sequence. , 2003, Biophysical journal.

[27]  Christodoulos A Floudas,et al.  Integrated computational and experimental approach for lead optimization and design of compstatin variants with improved activity. , 2003, Journal of the American Chemical Society.

[28]  Jeffrey J. Gray,et al.  Protein-protein docking with simultaneous optimization of rigid-body displacement and side-chain conformations. , 2003, Journal of molecular biology.

[29]  John L. Klepeis,et al.  Design of peptide analogues with improved activity using a novel de novo protein design approach , 2004 .

[30]  J L Klepeis,et al.  A new pairwise folding potential based on improved decoy generation and side‐chain packing , 2004, Proteins.

[31]  R. Siliciano,et al.  Novel Single-Cell-Level Phenotypic Assay for Residual Drug Susceptibility and Reduced Replication Capacity of Drug-Resistant Human Immunodeficiency Virus Type 1 , 2004, Journal of Virology.

[32]  David Baker,et al.  Exploring folding free energy landscapes using computational protein design. , 2004, Current opinion in structural biology.

[33]  Carlos Toro,et al.  Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV‐infected patients experiencing prolonged virologic failure , 2004, Journal of medical virology.

[34]  Tanja Kortemme,et al.  Computational design of protein-protein interactions. , 2004, Current opinion in chemical biology.

[35]  P. Güntert.  Automated NMR structure calculation with CYANA. , 2004, Methods in molecular biology.

[36]  David Baker,et al.  Protein Structure Prediction Using Rosetta , 2004, Numerical Computer Methods, Part D.

[37]  Bruce Randall Donald,et al.  A Novel Ensemble-Based Scoring and Search Algorithm for Protein Redesign and Its Application to Modify the Substrate Specificity of the Gramicidin Synthetase A Phenylalanine Adenylation Enzyme , 2005, J. Comput. Biol..

[38]  Jeffrey J. Gray,et al.  CAPRI rounds 3–5 reveal promising successes and future challenges for RosettaDock , 2005, Proteins.

[39]  Christopher T. Saunders,et al.  Recapitulation of protein family divergence using flexible backbone protein design. , 2005, Journal of molecular biology.

[40]  David A. Price,et al.  Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity , 2005, Antimicrobial Agents and Chemotherapy.

[41]  Thomas C. Quinn,et al.  Neutralizing Antibodies Do Not Mediate Suppression of Human Immunodeficiency Virus Type 1 in Elite Suppressors or Selection of Plasma Virus Variants in Patients on Highly Active Antiretroviral Therapy , 2006, Journal of Virology.

[42]  Christodoulos A. Floudas,et al.  Advances in protein structure prediction and de novo protein design : A review , 2006 .

[43]  Christodoulos A. Floudas,et al.  A novel high resolution CαCα distance dependent force field based on a high quality decoy set , 2006 .

[44]  H. Okada,et al.  Inhibition of HIV-1 infection by synthetic peptides derived CCR5 fragments. , 2007, Biochemical and biophysical research communications.

[45]  Shibo Jiang,et al.  HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. , 2007, Current pharmaceutical design.

[46]  Christodoulos A. Floudas,et al.  Novel formulations for the sequence selection problem in de novo protein design with flexible templates , 2007, Optim. Methods Softw..

[47]  Rongshi Li,et al.  Design and Synthesis of Human Immunodeficiency Virus Entry Inhibitors: Sulfonamide as an Isostere for the α-Ketoamide Group , 2007 .

[48]  T. Matthews,et al.  Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus , 2007, Proceedings of the National Academy of Sciences.

[49]  Bruce Randall Donald,et al.  Dead-End Elimination with Backbone Flexibility , 2007, ISMB/ECCB.

[50]  C A Floudas,et al.  Computational methods in protein structure prediction. , 2007, Biotechnology and bioengineering.

[51]  Michael S. Kay,et al.  Potent D-peptide inhibitors of HIV-1 entry , 2007, Proceedings of the National Academy of Sciences.

[52]  Ann Thayer,et al.  RESETTING PRIORITIES: The already challenging path to an HIV VACCINE takes a hard turn after recent clinical trials , 2008 .

[53]  Ann Thayer.  NEW ANTIRETROVIRALS: In recent years, new drugs have brought better options for CONTROLLING HIV , 2008 .

[54]  C A Floudas,et al.  Distance dependent centroid to centroid force fields using high resolution decoys , 2008, Proteins.

[55]  Yonghong Xiao,et al.  Design and Evaluation of Sifuvirtide, a Novel HIV-1 Fusion Inhibitor* , 2008, Journal of Biological Chemistry.

[56]  Shibo Jiang,et al.  Rationally Designed Anti-HIV Peptides Containing Multifunctional Domains as Molecule Probes for Studying the Mechanisms of Action of the First and Second Generation HIV Fusion Inhibitors* , 2008, Journal of Biological Chemistry.

[57]  Christodoulos A. Floudas,et al.  Biclustering via optimal re-ordering of data matrices in systems biology: rigorous methods and comparative studies , 2008, BMC Bioinformatics.

[58]  J. Sodroski,et al.  Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. , 2008, Structure.

[59]  Ann Thayer.  CONTAINED CHEMISTRY: Synthesizing HIGHLY POTENT COMPOUNDS is a lucrative and growing niche for custom chemical manufacturers , 2008 .

[60]  Lin Shen,et al.  Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs , 2008, Nature Medicine.

[61]  S. Sarafianos,et al.  SC29EK, a Peptide Fusion Inhibitor with Enhanced α-Helicity, Inhibits Replication of Human Immunodeficiency Virus Type 1 Mutants Resistant to Enfuvirtide , 2008, Antimicrobial Agents and Chemotherapy.

[62]  Martin S. Taylor,et al.  Toward full-sequence de novo protein design with flexible templates for human beta-defensin-2. , 2008, Biophysical journal.

[63]  Ann Thayer.  REACHING COMMON GROUND, GLOBALLY , 2008 .

[64]  Hong Lu,et al.  Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41. , 2008, Journal of medicinal chemistry.

[65]  Christodoulos A. Floudas,et al.  Computational de novo Peptide and Protein Design: Rigid Templates versus Flexible Templates , 2008 .

[66]  K. Kitaura,et al.  Design of Peptide-based Inhibitors for Human Immunodeficiency Virus Type 1 Strains Resistant to T-20* , 2009, Journal of Biological Chemistry.

[67]  Alexander Berchanski,et al.  Computer-based design of novel HIV-1 entry inhibitors: neomycin conjugated to arginine peptides at two specific sites , 2009, Journal of molecular modeling.

[68]  M. Matsuoka,et al.  Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide. , 2009, The international journal of biochemistry & cell biology.

[69]  John P. Moore,et al.  Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency , 2009, Proceedings of the National Academy of Sciences.

[70]  Kendra M. Haney,et al.  Comparative Docking Study of Anibamine as the First Natural Product CCR5 Antagonist in CCR5 Homology Models , 2009, J. Chem. Inf. Model..

[71]  NMR second site screening for structure determination of ligands bound in the hydrophobic pocket of HIV-1 gp41. , 2009, Journal of the American Chemical Society.

[72]  Christodoulos A. Floudas,et al.  A network flow model for biclustering via optimal re-ordering of data matrices , 2010, J. Glob. Optim..

[73]  H. K. Fung,et al.  New compstatin variants through two de novo protein design frameworks. , 2010, Biophysical journal.

[74]  K. Kiick,et al.  Manipulation of electrostatic and saccharide linker interactions in the design of efficient glycopolypeptide-based cholera toxin inhibitors. , 2010, Macromolecular bioscience.